BioCryst BCX7353 APeX-1 Interim Analysis 2017

BioCryst presents interim results from the APeX-1 Phase 2 study of BCX7353, an oral kallikrein inhibitor for hereditary angioedema. The 350 mg once-daily dose demonstrated statistically significant reductions in angioedema attacks with a favorable safety profile in patients with severe disease.